Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 177

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Phase II Study of Pembrolizumab As First-Line, Single-Drug Therapy for Patients With Unresectable Cutaneous Squamous Cell Carcinomas

Maubec, Eve, Boubaya, Marouane, Petrow, Peter, Beylot-Barry, Marie, Basset-Seguin, Nicole, Deschamps, Lydia, Grob, Jean-Jacques, Dréno, Brigitte, Scheer-Senyarich, Isabelle, Bloch-Queyrat, Coralie, Leccia, Marie-Thérèse, Stefan, Andreea, Saiag, Philippe, Grange, Florent, Meyer, Nicolas, de Quatrebarbes, Julie, Dinulescu, Monica, Legoupil, Delphine, Machet, Laurent, Dereure, Olivier, Zehou, Ouidad, Montaudié, Henri, Wierzbicka-Hainaut, Ewa, Le Corre, Yannick, Mansard, Sandrine, Guégan, Sarah, Arnault, Jean-Philippe, Dalac, Sophie, Aubin, François, Alloux, Céline, Lopez, Isabelle, Cherbal, Soufian, Tibi, Annick, Lévy, Vincent, on behalf of Groupe de Cancérologie Cutanée · 2020 · Journal of Clinical Oncology

Abstract

PURPOSE: To evaluate first-line pembrolizumab monotherapy efficacy and safety in patients with unresectable cutaneous squamous cell carcinomas (CSCCs). PATIENTS AND METHODS: Patients, predominantly men, with their CSSCs’ immunohistochemically determined programmed cell death-ligand 1 (PD-L1) status determined (tumor proportion score threshold, 1%), received pembrolizumab (200 mg every 3 weeks). The primary endpoint was the 39-patient primary cohort’s objective response rate at week 15 (ORR W15). Secondary objectives were best ORR, overall survival (OS), progression-free survival (PFS), duration of response (DOR), safety, ORR according to PD-L1 status and health-related quality of life using Functional Assessment of Cancer Therapy–General (FACT-G) score. An 18-patient expansion cohort, recruited to power the study to evaluate the ORR W15 difference between PD-L1+ and PD-L1– patients, was assessed for ORR, disease control rate, and safety, but not survival. RESULTS: Median age of all patients was 79 years. The primary cohort’s ORR W15 was 41% (95% CI, 26% to 58%), including 13 partial and 3 complete responses. Best responses were 8 partial and 8 complete responses. At a median follow-up of 22.4 months, respective median PFS, DOR, and OS were 6.7 months, not reached, and 25.3 months, respectively. Pembrolizumab-related adverse events affected 71% of the patients, and 4 (7%) were grade ≥ 3. One death was related to rapid CSCC progression; another resulted from a fatal second aggressive head and neck squamous cell carcinoma diagnosed 15 weeks postinclusion. ORR W15 for the entire population was 42%; it was significantly higher for PD-L1+ patients (55%) versus PD-L1– patients (17%; P = .02). Responders’ W15 total FACT-G score had improved ( P = .025) compared with nonresponders. CONCLUSION: First-line pembrolizumab monotherapy exhibited promising anti-CSCC activity, with durable responses and manageable safety. PD-L1 positivity appears to be predictive of pembrolizumab efficacy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.19.03357

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 177

Metadata

Authors
Maubec, E., Boubaya, M., Petrow, P., Beylot-Barry, M., Basset-Seguin, N., Deschamps, L., Grob, J.-J., Dréno, B., Scheer-Senyarich, I., Bloch-Queyrat, C., Leccia, M.-T., Stefan, A., Saiag, P., Grange, F., Meyer, N., de Quatrebarbes, J., Dinulescu, M., Legoupil, D., Machet, L., Dereure, O., Zehou, O., Montaudié, H., Wierzbicka-Hainaut, E., Le Corre, Y., Mansard, S., Guégan, S., Arnault, J.-P., Dalac, S., Aubin, F., Alloux, C., Lopez, I., Cherbal, S., Tibi, A., Lévy, V., & Cutanée, O. B. O. G. D. C.
Venue
Journal of Clinical Oncology
Published
2020-09-10
Volume
38
Issue
26
Pages
3051-3061
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W3046607405
Cited by
177
References
6
FWCI
17.05
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.